Goldman Sachs
PRLD icon

Goldman Sachs’s Prelude Therapeutics PRLD Stock Holding History

Goldman Sachs’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$644K Sell
120,834
-115,635
-49% -$503K ﹤0.01% 5545
2026
Q1 		$809K Buy
236,469
+118,992
+101% +$312K ﹤0.01% 5249
2025
Q4 		$341K Buy
117,477
+38,150
+48% +$64.4K ﹤0.01% 5799
2025
Q3 		$114K Sell
79,327
-69,851
-47% -$70K ﹤0.01% 6060
2025
Q2 		$121K Sell
149,178
-6,037
-4% -$5.23K ﹤0.01% 5781
2025
Q1 		$119K Buy
155,215
+6,889
+5% +$6.43K ﹤0.01% 5752
2024
Q4 		$189K Buy
148,326
+53,165
+56% +$70.5K ﹤0.01% 5658
2024
Q3 		$197K Buy
95,161
+20,238
+27% +$93.7K ﹤0.01% 5464
2024
Q2 		$285K Buy
74,923
+7,496
+11% +$30.5K ﹤0.01% 5127
2024
Q1 		$320K Sell
67,427
-2,038
-3% -$7.93K ﹤0.01% 4943
2023
Q4 		$297K Buy
69,465
+1,777
+3% +$5.41K ﹤0.01% 5010
2023
Q3 		$209K Buy
67,688
+43,900
+185% +$165K ﹤0.01% 5034
2023
Q2 		$107K Sell
23,788
-25,708
-52% -$154K ﹤0.01% 5348
2023
Q1 		$282K Buy
49,496
+33,732
+214% +$206K ﹤0.01% 5143
2022
Q4 		$95.2K Sell
15,764
-5,971
-27% -$38.3K ﹤0.01% 5488
2022
Q3 		$144K Sell
21,735
-22,560
-51% -$152K ﹤0.01% 5593
2022
Q2 		$232K Buy
44,295
+20,205
+84% +$103K ﹤0.01% 5572
2022
Q1 		$166K Sell
24,090
-89,245
-79% -$816K ﹤0.01% 5946
2021
Q4 		$1.41M Buy
113,335
+104,676
+1,209% +$1.7M ﹤0.01% 4546
2021
Q3 		$271K Sell
8,659
-9,958
-53% -$322K ﹤0.01% 5561
2021
Q2 		$533K Sell
18,617
-24,892
-57% -$886K ﹤0.01% 5169
2021
Q1 		$1.89M Buy
+43,509
New +$2.89M ﹤0.01% 4050
2020
Q4 		– Sell
-83,200
Closed -$2.51M – 5657
2020
Q3 		$2.51M Buy
+83,200
New +$2.35M ﹤0.01% 3411

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Goldman Sachs's PRLD Position: Q2 2026 in Review

Goldman Sachs reduced its Prelude Therapeutics (PRLD) stake by 49% in Q2 2026, selling an estimated $503K and leaving 120,834 shares worth $644K. The position accounts for ﹤0.01% of the portfolio, ranked #5545.

Goldman Sachs first reported a position in PRLD in Q3 2020 and has held it in 23 quarters since. The position peaked at $2.51M in Q3 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Goldman Sachs held 120,834 shares of Prelude Therapeutics worth $644K as of Q2 2026.
  • Goldman Sachs sold 115,635 Prelude Therapeutics shares in Q2 2026, an estimated $503K.
  • Prelude Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5545 holding.
  • Goldman Sachs first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Prelude Therapeutics position peaked at $2.51M in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.